Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients - PubMed (original) (raw)
Clinical Trial
Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients
K Budde et al. Am J Transplant. 2010 Mar.
Free article
Abstract
Sotrastaurin, a novel protein-kinase-C inhibitor, blocks early T-cell activation. In this 12-month, Phase II study, de novo renal-transplant patients were randomized to sotrastaurin (200 mg b.i.d.) + standard-exposure tacrolimus (SET) or reduced-exposure tacrolimus (RET) (SET: n = 76; RET: n = 66), or control (SET + mycophenolic acid [MPA, 720 mg b.i.d.]; n = 74). In both sotrastaurin groups, patients were converted from tacrolimus to MPA after Month 3, achieving calcineurin inhibitor-free immunosuppression. The primary endpoint was composite efficacy failure (treated biopsy-proven acute rejection, graft loss, death or loss to follow-up). The key secondary endpoint was glomerular filtration rate (GFR). Composite efficacy failure rates were: 4.1%, 5.4% and 1.5% at Month 3 (preconversion) and 7.8%, 44.8% and 34.1% at study end in the control, sotrastaurin + SET and sotrastaurin + RET groups, respectively; these results led to premature study discontinuation. Median GFR at Month 6 was: 57.0, 53.0 and 60.0 mL/min/1.73 m(2), respectively. Study-drug discontinuations due to adverse events occurred in 16.2%, 18.4% and 12.1%, respectively. Leukopenia and neutropenia occurred more frequently preconversion in control versus sotrastaurin groups: 13.7%, 5.6%, and 4.6%; and 11.1%, 4.3% and 3.1%, respectively. The initial sotrastaurin + tacrolimus regimen was efficacious and well tolerated but the postconversion sotrastaurin + MPA regimen showed inadequate efficacy. Longer-term evaluation of sotrastaurin + tacrolimus is warranted.
Similar articles
- Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients.
Friman S, Arns W, Nashan B, Vincenti F, Banas B, Budde K, Cibrik D, Chan L, Klempnauer J, Mulgaonkar S, Nicholson M, Wahlberg J, Wissing KM, Abrams K, Witte S, Woodle ES. Friman S, et al. Am J Transplant. 2011 Jul;11(7):1444-55. doi: 10.1111/j.1600-6143.2011.03538.x. Epub 2011 May 12. Am J Transplant. 2011. PMID: 21564523 Clinical Trial. - Efficacy of sotrastaurin plus tacrolimus after de novo kidney transplantation: randomized, phase II trial results.
Russ GR, Tedesco-Silva H, Kuypers DR, Cohney S, Langer RM, Witzke O, Eris J, Sommerer C, von Zur-Mühlen B, Woodle ES, Gill J, Ng J, Klupp J, Chodoff L, Budde K. Russ GR, et al. Am J Transplant. 2013 Jul;13(7):1746-56. doi: 10.1111/ajt.12251. Epub 2013 May 13. Am J Transplant. 2013. PMID: 23668931 Clinical Trial. - Sotrastaurin in calcineurin inhibitor-free regimen using everolimus in de novo kidney transplant recipients.
Tedesco-Silva H, Kho MM, Hartmann A, Vitko S, Russ G, Rostaing L, Budde K, Campistol JM, Eris J, Krishnan I, Gopalakrishnan U, Klupp J. Tedesco-Silva H, et al. Am J Transplant. 2013 Jul;13(7):1757-68. doi: 10.1111/ajt.12255. Epub 2013 May 9. Am J Transplant. 2013. PMID: 23659755 Clinical Trial. - Overview of sotrastaurin clinical pharmacokinetics.
Kovarik JM, Slade A. Kovarik JM, et al. Ther Drug Monit. 2010 Oct;32(5):540-3. doi: 10.1097/FTD.0b013e3181ee9e26. Ther Drug Monit. 2010. PMID: 20683390 Review. - Sotrastaurin, a protein kinase C inhibitor for the prevention of transplant rejection and treatment of psoriasis.
Manicassamy S. Manicassamy S. Curr Opin Investig Drugs. 2009 Nov;10(11):1225-35. Curr Opin Investig Drugs. 2009. PMID: 19876790 Review.
Cited by
- Long-Term Outcome after Early Mammalian Target of Rapamycin Inhibitor-Based Immunosuppression in Kidney Transplant Recipients.
Liefeldt L, Waiser J, Bachmann F, Budde K, Friedersdorff F, Halleck F, Lachmann N, Peters R, Rudolph B, Ünlü S, Wu K, Glander P. Liefeldt L, et al. J Clin Med. 2024 Jul 23;13(15):4305. doi: 10.3390/jcm13154305. J Clin Med. 2024. PMID: 39124572 Free PMC article. - Protein Kinase C Inhibitors Reduce SARS-CoV-2 Replication in Cultured Cells.
Huang C, Feng F, Shi Y, Li W, Wang Z, Zhu Y, Yuan S, Hu D, Dai J, Jiang Q, Zhang R, Liu C, Zhang P. Huang C, et al. Microbiol Spectr. 2022 Oct 26;10(5):e0105622. doi: 10.1128/spectrum.01056-22. Epub 2022 Aug 24. Microbiol Spectr. 2022. PMID: 36000889 Free PMC article. - Key driver genes as potential therapeutic targets in renal allograft rejection.
Yi Z, Keung KL, Li L, Hu M, Lu B, Nicholson L, Jimenez-Vera E, Menon MC, Wei C, Alexander S, Murphy B, O'Connell PJ, Zhang W. Yi Z, et al. JCI Insight. 2020 Aug 6;5(15):e136220. doi: 10.1172/jci.insight.136220. JCI Insight. 2020. PMID: 32634125 Free PMC article. - Discovery of Selective, Orally Bioavailable Pyrazolopyridine Inhibitors of Protein Kinase Cθ (PKCθ) That Ameliorate Symptoms of Experimental Autoimmune Encephalomyelitis.
Collier PN, Twin HC, Knegtel RMA, Boyall D, Brenchley G, Davis CJ, Keily S, Mak C, Miller A, Pierard F, Settimo L, Bolton CM, Chiu P, Curnock A, Doyle E, Tanner AJ, Jimenez JM. Collier PN, et al. ACS Med Chem Lett. 2019 Jun 27;10(8):1134-1139. doi: 10.1021/acsmedchemlett.9b00134. eCollection 2019 Aug 8. ACS Med Chem Lett. 2019. PMID: 31417666 Free PMC article. - High frequency of valganciclovir underdosing for cytomegalovirus prophylaxis after renal transplantation.
Rissling O, Naik M, Brakemeier S, Schmidt D, Staeck O, Hohberger A, Neumayer HH, Budde K. Rissling O, et al. Clin Kidney J. 2018 Aug;11(4):564-573. doi: 10.1093/ckj/sfx145. Epub 2018 Jan 12. Clin Kidney J. 2018. PMID: 30094022 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical